by Alison Kanski
NEW YORK – Personalized phone discussions about genetic risk assessment increased the number of breast and ovarian cancer patients who got genetic testing or discussed their risk with a genetic counselor, a study from Rutgers Cancer Institute … Read more
by Justin Jackson
An international team led by researchers from MacCallum Cancer Center in Melbourne, Australia, examined 391 tumor tissues from about 270 multisite autopsy samples collected from 15 individuals with end-stage high-grade serous ovarian cancer (HGSC). All of the … Read more
Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease
PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more
by British Medical Journal
Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer results in earlier stage diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of … Read more
Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.
Presenting results from the … Read more
by Mark L. Fuerst
Most people with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and the majority have not had genetic testing.
In a recent article in the ASCO Educational Book, Melissa Frey, MD, MS, … Read more
by Cedars-Sinai
New Studies Led by Cedars-Sinai Investigators Help Pinpoint Genetic Risk Factors Tied to Increased Risk of Ovarian Cancer and Suggest How to Better Identify Women Most At Risk
Image on left: Simon Gayther, PhD, professor of Biomedical Sciences, … Read more
by Karen Blum
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,
by Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
by Mike Bassett
— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more
by Erin Hunter
Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.
A new study shows that access to clinician
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
For … Read more
by Alison Kanski
NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more
by Ariana Pelosci
Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.
Patients with advanced solid tumors who have ATM gene alterations
by Charles Bankhead
— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk
The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more
by Caren Begun
Tennis legend Chris Evert—known for her 18-time grand slam success in the sport—has made recent headlines after revealing an early-stage ovarian cancer diagnosis and speaking out to help others by sharing her personal experience.
According to the … Read more
by M. Alexander Otto, MMS, PA
Despite unequivocal recommendations for universal germline BRCA testing in women with ovarian cancer, an analysis of a large commercial insurance database between 2008 and 2018 found that only about one third (33.9%) of such … Read more
by Cedars-Sinai
Findings Hold Potential for Predicting Many Years in Advance Which Women With the BRCA-1 Mutation Will Develop Disease
Newswise — Los Angeles (December 28, 2021). –Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S., … Read more
by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
